Cancer cell · 2012
Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs.
Клиническое исследованиеСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Van der Veldt Astrid A M, Lubberink Mark, Bahce Idris, Walraven Maudy, de Boer Michiel P, Greuter Henri N J M, Hendrikse N Harry, Eriksson Jonas, Windhorst Albert D, Postmus Pieter E, Verheul Henk M, Serné Erik H, Lammertsma Adriaan A, Smit Egbert F
Аннотация
Current strategies combining anti-angiogenic drugs with chemotherapy provide clinical benefit in cancer patients. It is assumed that anti-angiogenic drugs, such as bevacizumab, transiently normalize abnormal tumor vasculature and contribute to improved delivery of subsequent chemotherapy. To investigate this concept, a study was performed in non-small cell lung cancer (NSCLC) patients using positron emission tomography (PET) and radiolabeled docetaxel ([(11)C]docetaxel). In NSCLC, bevacizumab reduced both perfusion and net influx rate of [(11)C]docetaxel within 5 hr. These effects persisted after 4 days. The clinical relevance of these findings is notable, as there was no evidence for a substantial improvement in drug delivery to tumors. These findings highlight the importance of drug scheduling and advocate further studies to optimize scheduling of anti-angiogenic drugs.
Предметные рубрики MeSH
AgedAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBevacizumabBone MarrowCarcinoma, Non-Small-Cell LungDocetaxelDrug Administration ScheduleFemaleHumansLung NeoplasmsMaleMetabolic Clearance RateMiddle AgedNeovascularization, PathologicPositron-Emission TomographyTaxoidsThyroid GlandVascular Endothelial Growth Factor A